Skip to contentHome page Seeking Alpha - Power to InvestorsTranscriptsSwitzerlandSep. 29, 2025 6:07 PM ETMoonLake Immunotherapeutics (MLTX) StockMLTXSA Transcripts155.64K FollowersMoonLake Immunotherapeutics - Special CallCompany ParticipantsMatthias Bodenstedt - Chief Financial OfficerJorge da Silva - Co-Founder, CEO & DirectorKristian ReichConference Call ParticipantsAlexa Kimball - Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center, Inc.PresentationMatthias BodenstedtChief Financial OfficerWelcome, everyone. Good morning, good afternoon. Thank you for joining today's webcast. My name is Matthias Bodenstedt, I'm the Chief Financial Officer of MoonLake Immunotherapeutics. As usual, I'm joined here by our Co-Founder and CSO, Kristian Reich; our Co-Founder and CEO, Jorge da Silva. We are also honored to be joined today by Professor Alexa Kimball, a leading [indiscernible] in HS. We will go through the data and then look forward to the thoughts and reflections of Professor Kimball on the VELA data that we will be presenting today. In the end of the session, as usual, we will open up for Q&A.Please take note of our disclaimer on the forward-looking statements. [Operator Instructions]. The presentation document and the replay of this presentation will be made available on our IR website on moonlaketx.com. With that, I'm handing over to Jorge.Jorge da SilvaCo-Founder, CEO & DirectorThank you, Matthias. Also from my side, welcome all. Good morning, good afternoon, depending on where you are. Thank you for making the time to join our presentation today.I'll start very briefly with a quick summary of the points that we're going to be hitting in the call today, most of which obviously has been covered in the press release that was sent out yesterday.The main messages are that obviously, the VELA-1 and VELA-2 trials formed the VELA program, which, as you know, has been testing sonelokimab in adults with moderate to severe HS to a primary endpoint readout at week 16. Importantly, from a regulatory perspective, and obviously, for all of us, theRead more current MLTX analysis and newsView all earnings call transcriptsCommentsRecommended For YouAbout MLTX StockSymbolLast Price% Chg1D5D1M6M1Y5Y10YMarket CapRev Growth (YoY)Short InterestPrev. CloseMore on MLTXTrending AnalysisTrending NewsSeeking Alpha - Power to InvestorsPower to InvestorsFollow usDownload appContact usSubscription Support: 1-347-509-6837© 2025 Seeking AlphaTo ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.Is this happening to you frequently? Please report it on our feedback forum.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.